Sign inJoin waitlistJoin the waitlist

Andrew Bukowinski

Clinical Director, Oncology · UPMC Medical Education

Credentials: · · · ·

History

Oncology · UPMC Medical Education
Present
Univ of Pittsburgh Sch of Med
Present

Pediatric Hematology Oncology
Cincinnati Children's Hospital Medical Center
2014–2015
Pediatrics
UPMC Children's Hospital of Pittsburgh
2009–2012
Clinical and Translational Research, University of Cincinnati
University at Buffalo School of Medicine and Biomedical Sciences
2005–2009
Psychology, Western New England College
2001–2005

Research

Toxicity of Cancer Therapy in Adolescents and Young Adults (AYAs)
Review · Seminars in Oncology Nursing · 2015 · First of 5 authors · 41 citations
A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial…
Pediatric Blood & Cancer · 2021 · First of 9 authors · 37 citations
Intracranial Myxoid Mesenchymal Tumor with Rare EWSR1-CREM Translocation
Case report · Pediatric Neurosurgery · 2019 · 32 citations

Catherine Gestrich
2 papers
EM
Erica Mamauag
2 papers
Erika Friehling
2 papers
Holly Edington
2 papers
James Ford
2 papers
Jeremy Rubinstein
2 papers
Jessica Pollard
2 papers
Joanna Robles
2 papers
John Skaugen
2 papers
Julie Krystal
2 papers
Julie Rivers
2 papers
Karen Chisholm
2 papers

Clinical trials

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Principal investigator · Completed · Phase 1
National Cancer Institute (NCI)
2017–2021
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Site PI · Recruiting · Phase 1
Children's Oncology Group
2025–2028
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Site PI · Recruiting · Phase 1, Phase 2
Children's Oncology Group
2022–2026
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Children's Oncology Group
2021–2028